Relationship Between Depressive Symptoms and Health Status in Peripheral Artery Disease: Role of Sex Differences

Qurat-ul-ain Jelani, MD; Carlos Mena-Hurtado, MD; Matthew Burg, PhD; Robert Soufer, MD; Kensey Gosch, MS; Philip G. Jones, MS; John A. Spertus, MD; Basmah Safdar, MD; Kim G. Smolderen, PhD

BACKGROUND: The association of depressive symptoms with health status in peripheral artery disease (PAD) is understudied. No reports of differential impact on women have been described.

METHODS AND RESULTS: The PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Artery Disease Investigating Trajectories) registry enrolled 1243 patients from vascular specialty clinics with new or worsening PAD symptoms. Depressive symptoms were assessed at baseline and 3 months using the 8-Item Patient Health Questionnaire (score ≥10 indicating clinically relevant depressive symptoms). Disease-specific and generic health status were measured by Peripheral Artery Questionnaire and EQ-5D Visual Analogue Scale at baseline and 3, 6, and 12 months. An adjusted general linear model for repeated measures was constructed for baseline and 3-, 6-, and 12-month health status outcomes by depressive symptoms at baseline. Differences by sex were tested with interaction effects. The mean age was 67.6±9.4 years with 38% (n=470) women. More women than men (21.1% versus 12.9%; \(P<0.001\)) presented with severe depressive symptoms. In the adjusted model, patients with depressive symptoms had worse health status at each time point (all \(P<0.0001\)). Results were similar for EQ-5D Visual Analogue Scale scores. The magnitude in 1-year change in health status scores did not differ by sex. Depressive symptoms explained 19% of the association between sex differences in 1-year Peripheral Artery Questionnaire summary scores.

CONCLUSIONS: Women with PAD have a high burden of depressive symptoms. Depressive symptoms were associated with a strikingly worse disease-specific health status recovery path over the year following PAD diagnosis in men and women. Developing and testing interventions to address depressive symptoms in PAD are urgently needed.

REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01419080.

Key Words: depressive symptoms ▪ health status ▪ peripheral artery disease ▪ sex differences

Peripheral artery disease (PAD) remains a significant health problem,\(^1\) affecting >200 million people worldwide\(^2\) and >8 million people >40 years of age in the United States alone.\(^3,4\) In patients with multiple atherosclerotic risk factors, including smoking and diabetes mellitus,\(^5\) the prevalence of PAD can be as high as 30%.\(^6\) PAD is associated with a high risk of cardiovascular mortality and morbidity,\(^7,8\) with a disproportionate high risk of cardiovascular events compared with coronary artery disease and cerebrovascular disease.\(^9\) From a societal perspective, PAD is a costly disease. Total annual costs associated with PAD-related hospitalizations in the United States are estimated to be in excess of $21 billion,\(^10\) which will continue to increase as the population ages.

The disability associated with PAD is significant. PAD may present itself as excruciating pain while walking and may impact patients’ mobility and
functioning, as well as their health status and quality of life. Although PAD presents itself at least as commonly in women as in men, women’s experiences of the disease burden may be worse than that of men’s, as expressed by greater functional impairment, worse health-related quality of life, and poorer outcomes after lower extremity revascularization procedures. Women diagnosed with cardiovascular disease are also at a much higher risk of presenting with depressive symptoms compared with men. The manifestation of depressive symptoms is independently associated with higher cardiac and all-cause mortality, rehospitalization, and worse functional status, including angina and quality of life after myocardial infarction. Depressive symptoms are also more common in women with PAD than in men with PAD. Although depressive symptoms are known to be associated with a more dramatic annual decline in functional performance, reduced walking distance, less quality-of-life benefit after revascularization, and an increased risk of death/major adverse cardiovascular events, coronary heart disease, and contralateral PAD events, it is unclear as to what extent depressive symptoms may be associated with a worse health status recovery profile in patients with PAD, and whether women are affected differently than men.

To address this gap in knowledge, we sought to (1) determine the prevalence of depressive symptoms and their treatment; (2) compare the trajectory of 1-year PAD-specific health status following a new or worsening PAD diagnosis as a function of depressive symptoms; and (3) explore sex differences in both the prevalence and health status impact of depressive symptoms among patients with PAD. We hypothesized that women with PAD have a higher burden of depressive symptoms compared with men with PAD, both at baseline and in the year following a new or worsening PAD diagnosis, and that depressive symptoms would be associated with worse health status outcomes over time. Establishing PAD-specific health status recovery profiles as a function of depressive symptoms can underscore the importance of this comorbidity, especially in women, and stimulate new research into ways to address this problem in a more holistic approach to PAD care.

**METHODS**

Data requests for the PORTRAIT study can be submitted to the corresponding author. Because of the sensitive nature of the data collected for this study, requests to access a deidentified data set from qualified researchers trained in human subject confidentiality protocols may be considered on an individual basis by contacting the corresponding author or by contacting the PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Artery Disease Investigating Trajectories) registry group on the website.

Patients included in this study were enrolled from the PORTRAIT registry, for which the methods have previously been described. Briefly, it is an international, prospective, observational study designed to address gaps in knowledge about the quality of care and health status outcomes of patients with PAD. Between June 2011 and December 2015, 1275 patients with a new diagnosis of PAD or those with an exacerbation of symptoms presenting to 16 vascular specialty clinics were enrolled. Of these 16 vascular specialty clinics, 10 were from the United States, 5 were from The Netherlands, and 1 was from Australia. Patients from The Netherlands and Australia were included in this study as PAD has become a global health problem with high morbidity and mortality.
characteristics, treatment patterns, and outcomes and help improve practices. Patients with a Doppler resting ankle-brachial index (ABI) ≤0.90 or a significant decrease in postexercise ankle pressure of ≥20 mmHg were enrolled in the study. Other inclusion criteria included (1) patients aged ≥18 years; (2) new-onset or recent exacerbation of exertional leg symptoms, regardless of whether symptoms were typical (buttock, thigh, hip, or calf pain; numbness or discomfort inhibiting the patient’s ability to walk distances) or atypical. To classify patients’ symptoms as atypical or typical, the coordinators were instructed to abstract this from patients’ medical records and as described by their treating physician. Patients with a noncompressible ABI ≥1.30, those who underwent a lower-limb revascularization procedure in the past year (angioplasty, bypass surgery, atherectomy, or endarterectomy) for the ipsilateral leg relative to where the patient was currently having symptoms, patients with a current episode of critical limb ischemia (ischemic rest pain, ulceration, or gangrene; Fontaine III or IV; or Rutherford category 4–6), patients who could not speak English, Spanish, or Dutch, and patients with hearing impairment or current imprisonment were excluded. Approval from the institutional review board of each participating site was obtained, and participants provided informed consent for all study procedures and interviews. All patients provided consent to have their medical data abstracted from their electronic medical records. A 2-step process was designed to obtain medical record information from outside the enrolling facility: (1) during follow-up, patients were asked whether they obtained care outside of the enrolling facility; and (2) if patients indicated they obtained outside care, their medical record information was requested per the patient’s consent that was obtained on enrollment.

### Data Collection and Study Definitions

Information on patients’ baseline characteristics was obtained by trained personnel using medical chart abstraction as well as in-person interviews during the first visit and before initiation of treatment. On enrollment, detailed information was obtained through chart abstraction on demographics, cardiac risk factors, comorbidities, disease severity from diagnostic tests, and baseline treatment (medications, cardiovascular risk management strategies, and referrals). Follow-up assessments were conducted by a centralized call center at 3, 6, and 12 months using standardized interviews. Information on the primary PAD treatment strategy was determined at 3 months as either noninvasive (medical therapy, including pharmacologic treatment and smoking cessation counseling) or invasive treatment (including either surgical or endovascular intervention). Primary PAD treatment information from all US sites was adjudicated by a central committee; from non-US sites, patient-reported information was used.

### Assessment of Depressive Symptoms

Depressive symptoms were assessed using the 8-Item Patient Health Questionnaire (PHQ-8), an 8-item depression scale that has been established as a valid screening tool to screen for a major depressive disorder, as well as to quantify the frequency of depressive symptoms experienced in the past 2 weeks. Scores range from 0 to 27, with a higher score indicating a higher level of depressive symptoms, and a score ≥10 has 88% sensitivity and specificity to detect major depression. The severity of depressive symptoms has been described using the following categories: “no” depressive symptoms if PHQ-8 scores are <5, mild depressive symptoms for PHQ-8 scores ≥5 and ≤9, and moderate/severe depressive symptoms for scores ≥10.

### Assessment of Outcomes

Health status was measured using the disease-specific Peripheral Artery Questionnaire (PAQ) and the generic EQ-5D Visual Analogue Scale (VAS) instrument. The PAQ is a 20-item, validated, PAD-specific, multidimensional health status instrument that measures 6 health status domains relevant to patients with PAD: physical function, symptoms, symptom stability, social limitations, treatment satisfaction, and quality of life. A summary score is calculated as the average of the physical limitation, symptoms, quality of life, and social functioning scores. Scores range from 0 to 100 points, with higher scores indicating better functioning.

The EQ-5D is a standardized generic measure of health status that provides a simple measure of health status for clinical assessment. The questionnaire consists of 2 parts: a descriptive section (EQ-5D index score) and a VAS (EQ-5D VAS score). We used the EQ-5D VAS score to assess patients’ overall health. The 20-cm VAS ranges from the worst (a score of 0) to the best (a score of 100) imaginable health state, with higher scores indicating better health status.

### Other Variables

Depression treatment information was derived from patients’ medical records. Information about counseling and/or pharmacologic treatment was abstracted from patients’ medical records at the time of their enrollment (up to 1 month after enrollment).

### Statistical Analysis

Patients’ baseline characteristics were compared by sex using \( \chi^2 \) tests or the Fisher exact test for categorical
variables and Student t tests for continuous variables. Categorical variables were organized as frequencies and percentages, and continuous variables were summarized as means and SDs or medians and interquartile ranges. For the covariates considered in the model, missingness was minimal, with only 1.5% of patients who had missing information for 1 covariate and only 1 patient who had missing information for 3 covariates. The highest number of covariate missingness was for “high school education” (n=10) and “avoiding care because of cost” (n=8); 98% of the total cohort had no missing covariate information. Given the minimal level of missingness, complete case analysis was used for our analyses.

Mean PHQ-8 depressive symptoms, as well as the dichotomous prevalence of clinically relevant depressive symptoms (PHQ-8 score ≥10), were summarized by sex at each time point.

General linear models (GLMs) for repeated measures, with a random effect for site, were used to study baseline and 3-, 6-, and 12-month health status outcomes by the presence of clinically relevant depressive symptoms (PHQ-8 ≥10 at baseline versus PHQ-8 score <10). We tested the 2-way interactions between time×sex, time×depressive symptoms, and depressive symptoms×sex as well as the 3-way interaction between sex×depressive symptoms×time. GLMs were created both for the PAQ summary and EQ-5D VAS scores over time. We selected the following covariates for multivariable modeling: age, country, White race, avoiding care because of cost, high school education, ABI, exacerbation of symptoms, bilateral disease, smoking, history of diabetes mellitus, coronary artery disease, and sleep apnea. Consistent with prior work, these covariates were chosen as these were previously identified as most explanatory for patients’ health status outcomes (PAQ summary scores) in the PORTRAIT registry.37 Estimates for health status differences by depressive symptom groups were presented as mean estimates, and depressive symptom group differences over time were summarized as least square means.

For descriptive purposes, and by ways of sensitivity analysis, we compared health status outcomes by severity of depression (no, mild, or moderate-severe), and performed post hoc testing. In addition, for the modeling, we performed 2 sensitivity analyses. First, we examined the degree to which depressive symptoms explained sex differences in disease-specific health status (PAQ summary score). We ran the fully adjusted GLM without depressive symptoms or interaction terms, containing only the main effect for sex. We then replicated the analysis while adding depressive symptoms to the model to examine the difference in estimates for the main sex effect. Second, we explored the potential effect of nonresponse bias. Baseline characteristics of those with and without complete follow-up were compared. Characteristics with a >10% standardized difference were added as covariates to the original GLM to determine if the estimated effects were different.

A 2-sided P<0.05 was considered statistically significant. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).

RESULTS

In terms of participation rate, of a total of 1636 patients screened, 1243 were enrolled in the study. Follow-up rates were 92% at 3 months, 88% at 6 months, and 87% at 12 months. With respect to those enrolled versus not enrolled in the study, there were no significant differences between the 2 groups in terms of age, sex, race, and insurance. Baseline characteristics of the total cohort (n=1243) stratified by sex and depressive symptoms (PHQ-8 ≥10) are shown in Tables 1 and 2. The mean age was 67.6±9.4 years, and 38% (n=470) were women. A total of 52.6% (n=654) had new-onset PAD symptoms, whereas 47.4% (n=589) had an exacerbation of symptoms at the time of enrollment.

At enrollment, there was no significant difference in age between women and men for the overall cohort (68.0±9.9 versus 67.3±9.2 years; P=0.23). Women were less likely to be married, less likely to be employed, and more likely than men to avoid care because of cost. Women were more likely to be sedentary during leisure time and were less likely to engage in moderate to strenuous exercise compared with their male counterparts. Compared with men, women had lower mean ABI values and were more likely to present with atypical symptoms and to present with bilateral symptoms. Cardiovascular risk management strategies were not different by sex, except for higher rates of unsupervised exercise therapy among women. There were no differences in the rates of invasive treatment at 3 months (either surgical or endovascular) by sex (Table 1).

In the overall cohort (n=1243), a total of 199 patients (16.0%) had moderate-severe depressive (PHQ-8 ≥10) symptoms on presentation, with rates being much higher in women than in men (21.1% versus 12.9%; P<0.001) at presentation. Mean PHQ-8 scores were 5.6±5.3 in women versus 4.2±4.8 in men at baseline (Table 1).

After stratification by sex and clinically relevant depressive symptoms (PHQ-8 ≥10), mean PHQ-8 scores among those with depressive symptoms were similar between men and women (14.2±3.7 versus 14.1±3.7). Of those with clinically relevant depressive symptoms, almost half of women and one third of men were on some form of depression treatment. A complete
### Table 1. Baseline Patient Characteristics, Stratified by Sex

| Characteristics                               | Women (n=470 [38%]) | Men (n=773 [62%]) | Total (n=1243) | P Value |
|-----------------------------------------------|----------------------|-------------------|----------------|---------|
| **Demographics and socioeconomic status**     |                      |                   |                |         |
| Age, y                                        | Mean±SD              |                   |                |         |
|                                               | 68.0±9.9             | 67.3±9.2          | 67.6±9.4       | 0.23    |
|                                               | Median (IQR)         |                   |                |         |
|                                               | 68.0 (61.0–75.0)     | 67.0 (61.0–73.0)  | 68.0 (61.0–74.0)|         |
| Race                                          |                      |                   |                | <0.001  |
| White                                         | 206 (63.0)           | 353 (78.8)        | 559 (72.1)     |         |
| Black                                         | 106 (32.4)           | 75 (16.7)         | 181 (23.4)     |         |
| Other                                         | 15 (4.6)             | 20 (4.5)          | 35 (4.5)       |         |
| Country                                       |                      |                   |                | <0.001  |
| United States                                 | 327 (69.6)           | 448 (58.0)        | 775 (62.3)     |         |
| The Netherlands                               | 117 (24.9)           | 257 (33.2)        | 374 (30.1)     |         |
| Australia                                     | 26 (5.5)             | 68 (8.8)          | 94 (7.6)       |         |
| Health insurance                              | 486 (99.1)           | 770 (99.6)        | 1236 (99.4)    | 0.44    |
| Education, high school or above               | 312 (66.8)           | 539 (70.4)        | 851 (69.0)     | 0.19    |
| Married                                       | 208 (44.4)           | 524 (68.1)        | 732 (59.2)     | <0.001  |
| Working for pay                               | 82 (17.5)            | 211 (27.4)        | 293 (23.6)     | <0.001  |
| Avoid care because of cost                    | 78 (16.8)            | 96 (12.5)         | 174 (14.1)     | 0.035   |
| **Activity during leisure time**              |                      |                   |                |         |
| Sedentary                                     | 240 (51.6)           | 258 (34.2)        | 498 (40.8)     | <0.001  |
| Mild                                          | 146 (31.4)           | 257 (34.0)        | 403 (33.0)     |         |
| Moderate                                      | 79 (17.0)            | 240 (31.8)        | 319 (26.1)     |         |
| **Risk factors and comorbidities**           |                      |                   |                |         |
| Smoking status                                |                      |                   |                |         |
| Never                                         | 79 (16.8)            | 53 (6.9)          | 132 (10.6)     | <0.001  |
| Former                                        | 213 (45.4)           | 435 (56.3)        | 648 (52.2)     |         |
| Current                                       | 177 (37.7)           | 284 (36.8)        | 461 (37.1)     |         |
| CAD                                          | 162 (34.5)           | 324 (41.9)        | 486 (39.1)     | 0.009   |
| Dyslipidemia                                  | 381 (81.1)           | 606 (78.4)        | 987 (79.4)     | 0.26    |
| Hypertension                                  | 404 (86.0)           | 589 (76.2)        | 993 (79.9)     | <0.001  |
| Diabetes mellitus                             | 168 (35.7)           | 247 (32.0)        | 415 (33.4)     | 0.17    |
| Congestive heart failure                      | 42 (8.9)             | 81 (10.5)         | 123 (9.9)      | 0.38    |
| Chronic kidney disease                        | 59 (12.6)            | 79 (10.2)         | 138 (11.1)     | 0.20    |
| Chronic back pain                             | 72 (15.3)            | 97 (12.5)         | 169 (13.6)     | 0.17    |
| Sleep apnea                                   | 32 (6.8)             | 68 (8.8)          | 100 (8.0)      | 0.21    |
| **PAD treatment history**                     |                      |                   |                |         |
| Amputation                                     | 3 (0.6)              | 13 (1.7)          | 16 (1.3)       | 0.11    |
| PAD bypass                                     | 27 (5.7)             | 72 (9.3)          | 99 (8.0)       | 0.024   |
| PAD endarterectomy                             | 13 (2.8)             | 24 (3.1)          | 37 (3.0)       | 0.73    |
| PAD athrectomy                                 | 11 (2.3)             | 20 (2.6)          | 31 (2.5)       | 0.79    |
| PAD angioplasty                                | 94 (20.0)            | 153 (19.8)        | 247 (19.9)     | 0.93    |
| Cilostazol                                     | 28 (6.0)             | 48 (6.2)          | 76 (6.1)       | 0.85    |
| Antiplatelet therapy                           | 323 (69.0)           | 518 (67.4)        | 841 (68.0)     | 0.54    |
| Statin                                        | 320 (68.4)           | 546 (71.0)        | 866 (70.0)     | 0.33    |
| **PAD characteristics on presentation**       |                      |                   |                |         |
| Symptoms                                       |                      |                   |                |         |
| New onset                                      | 244 (51.9)           | 410 (53.0)        | 654 (52.6)     | 0.70    |
| Exacerbation of symptoms                      | 226 (48.1)           | 363 (47.0)        | 589 (47.4)     |         |

(Continued)
Table 1. Continued

| Characteristics                        | Women (n=470 [38%]) | Men (n=773 [62%]) | Total (n=1243) | P Value |
|----------------------------------------|---------------------|-------------------|----------------|---------|
| ABI                                    |                     |                   |                |         |
| Mean±SD                                | 0.65±0.18           | 0.67±0.19         | 0.67±0.19      | 0.045   |
| Rutherford category                    |                     |                   |                |         |
| Mild claudication                      | 95 (20.7)           | 187 (24.5)        | 282 (23.1)     | 0.21    |
| Moderate claudication                  | 239 (52.1)          | 362 (47.4)        | 601 (49.1)     |         |
| Severe claudication                    | 125 (27.2)          | 215 (28.1)        | 340 (27.8)     |         |
| Duration of pain, mo                   |                     |                   |                |         |
| <1                                     | 10 (2.5)            | 20 (3.0)          | 30 (2.8)       | 0.38    |
| 1–6                                    | 129 (31.7)          | 191 (28.9)        | 320 (25.9)     |         |
| 7–12                                   | 78 (19.2)           | 110 (16.6)        | 188 (14.6)     |         |
| >12                                    | 190 (46.7)          | 341 (51.5)        | 531 (42.2)     |         |
| Atypical PAD symptoms                  | 75 (17.2)           | 88 (12.3)         | 163 (14.2)     | 0.020   |
| Bilateral disease                      | 264 (56.2)          | 364 (47.1)        | 628 (50.5)     | 0.001   |
| Lesion site                            |                     |                   |                |         |
| Proximal                               | 130 (27.8)          | 217 (28.3)        | 347 (28.1)     | 0.55    |
| Distal                                 | 149 (31.9)          | 223 (29.1)        | 372 (30.1)     |         |
| Both                                   | 188 (40.3)          | 327 (42.6)        | 515 (41.7)     |         |
| PAD treatment after enrollment         |                     |                   |                |         |
| Cilostazol                             | 62 (13.2)           | 85 (11.1)         | 147 (11.9)     | 0.25    |
| Antiplatelet therapy                   | 368 (78.6)          | 583 (75.8)        | 951 (76.9)     | 0.25    |
| Statin                                 | 370 (79.1)          | 629 (81.8)        | 999 (80.8)     | 0.24    |
| Smoking cessation physician advice     | 153 (71.2)          | 231 (64.9)        | 384 (67.3)     | 0.12    |
| Unsupervised PAD exercise therapy      | 200 (42.6)          | 249 (32.2)        | 449 (36.1)     | <0.001  |
| Supervised PAD exercise therapy        | 95 (20.2)           | 177 (22.9)        | 272 (21.9)     | 0.27    |
| Invasive treatment                     | 82 (19.9)           | 141 (20.1)        | 223 (20.0)     | 0.94    |
| Surgical treatment                     | 6 (1.5)             | 23 (3.3)          | 29 (2.6)       | 0.07    |
| Endovascular treatment                 | 78 (18.9)           | 122 (17.4)        | 200 (18.0)     | 0.51    |
| Depression severity and treatment at baseline |                     |                   |                |         |
| PHQ-8 score severity (baseline)        |                     |                   |                |         |
| None                                   | 257 (54.7)          | 510 (66.0)        | 767 (61.7)     |         |
| Mild (5 ≥ PHQ-8 < 9)                   | 114 (24.3)          | 163 (21.1)        | 277 (22.3)     | <0.001  |
| Moderate/severe (PHQ-8 ≥10)            | 99 (21.1)           | 100 (12.9)        | 199 (16.0)     |         |
| PHQ-8 depression score, mean±SD        | 5.6±5.3             | 4.2±4.8           | 4.7±5.0        | <0.001  |
| Baseline depression treatments          |                     |                   |                |         |
| None                                   | 331 (70.4)          | 660 (85.4)        | 991 (79.7)     | 0.001   |
| Pharmacologic treatment                | 79 (16.8)           | 71 (9.2)          | 150 (12.1)     |         |
| Counseling                             | 13 (2.8)            | 12 (1.6)          | 25 (2.0)       |         |
| Both                                   | 47 (10.0)           | 30 (3.9)          | 77 (6.2)       |         |
| Antidepressant use at baseline         |                     |                   |                |         |
| SSRI                                   | 72                  | 46                | 118            | <0.001  |
| SNRI                                   | 25                  | 12                | 37             | <0.001  |
| TCA                                    | 17                  | 14                | 31             | 0.06    |
| Atypical agents                        | 31                  | 29                | 60             | 0.03    |
| Miscellaneous                          |                     |                   |                |         |
| Perphenazine                           | 0                   | 1                 | 1              | 1.00    |

Continuous variables were compared using the Student t test. Categorical variables were compared using the χ² or the Fisher exact test (health insurance). Values are listed as number (percentage), unless otherwise described. ABI indicates ankle-brachial index; CAD, coronary artery disease; IQR, interquartile range; PAD, peripheral artery disease; PHQ-8, 8-Item Patient Health Questionnaire; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin receptor inhibitor; and TCA, tricyclic antidepressant.
### Table 2. Baseline Patient Characteristics, Stratified by Sex and Clinically Relevant Depressive Symptoms (PHQ-8 ≥10)

| Characteristics                        | Women                      | Men                      | P Value | P Value |
|----------------------------------------|----------------------------|--------------------------|---------|---------|
|                                        | PHQ-8 ≥10 (n=99)           | PHQ-8 <10 (n=371)        |         |         |
|                                        | PHQ-8 ≥10 (n=100)          | PHQ-8 <10 (n=673)        |         |         |
| Demographics and socioeconomic status  |                            |                          |         |         |
| Age, y                                 | Mean±SD 63.0±9.9           | 69.3±9.5                 | <0.001  | 63.3±8.9 | 67.9±9.0 | <0.001 |
| Race*                                  | White 47 (63.5)            | 159 (62.8)               |         | 50 (76.9) | 303 (79.1) |         |
|                                        | Black 19 (25.7)            | 87 (34.4)                | 0.013   | 8 (12.3)  | 67 (17.5)  | 0.031  |
|                                        | Other 8 (10.8)             | 7 (2.8)                  |         | 7 (10.8)  | 13 (3.4)   |         |
| Country                                | United States 74 (74.7)    | 253 (68.2)               |         | 65 (65.0) | 383 (56.9) |         |
|                                        | The Netherlands 15 (15.2)  | 102 (27.5)               | 0.006   | 23 (23.0) | 234 (34.8) | 0.05   |
|                                        | Australia 10 (10.1)        | 16 (4.3)                 |         | 12 (10.0) | 56 (8.3)   |         |
| Health insurance*                      | 95 (96.0)                 | 371 (100.0)              | 0.001   | 100 (100.0) | 670 (99.6) | 1.000  |
| Education, high school or above        | 59 (60.8)                 | 253 (68.4)               | 0.16    | 67 (67.7) | 472 (70.8) | 0.53   |
| Married                                | 34 (34.7)                 | 174 (47.0)               | 0.028   | 56 (56.6) | 468 (69.9) | 0.008  |
| Working for pay                        | 14 (14.3)                 | 68 (18.4)                | 0.34    | 20 (20.0) | 191 (28.5) | 0.08   |
| Avoid care because of cost            | 31 (32.0)                 | 47 (12.8)                | <0.001  | 23 (23.0) | 73 (10.9)  | <0.001 |
| Activity during leisure time           | Sedentary 64 (65.3)        | 176 (48.0)               |         | 62 (63.3) | 196 (29.8) |         |
|                                        | Mild 23 (23.5)             | 123 (33.5)               | 0.008   | 19 (19.4) | 238 (36.2) | <0.001 |
|                                        | Moderate 11 (11.2)         | 68 (18.5)                |         | 17 (17.3) | 223 (33.9) |         |
| Risk factors and comorbidities         |                            |                          |         |         |
| Smoking status*                        | Never 13 (13.3)            | 66 (17.8)                | 0.004   | 7 (7.0)  | 46 (6.8)   | 0.11   |
|                                        | Former 34 (34.7)           | 179 (48.2)               |         | 47 (47.0) | 388 (57.7) |         |
|                                        | Current 51 (52.0)          | 126 (34.0)               |         | 46 (46.0) | 238 (35.4) |         |
| CAD                                    | 43 (43.4)                 | 119 (32.1)               | 0.034   | 48 (48.0) | 276 (41.0) | 0.19   |
| Dyslipidemia                           | 82 (82.8)                 | 299 (80.6)               | 0.81    | 74 (74.0) | 532 (79.0) | 0.25   |
| Hypertension                           | 85 (85.9)                 | 319 (86.0)               | 0.97    | 77 (77.0) | 512 (76.1) | 0.84   |
| Diabetes mellitus                      | 47 (47.5)                 | 121 (32.6)               | 0.006   | 34 (34.0) | 213 (31.6) | 0.64   |
| Congestive heart failure               | 9 (9.1)                   | 33 (8.9)                 | 0.95    | 16 (16.0) | 65 (9.7)   | 0.05   |
| Chronic kidney disease                 | 14 (14.1)                 | 45 (12.1)                | 0.59    | 8 (8.0)   | 71 (10.5)  | 0.43   |
| Chronic back pain                      | 17 (17.2)                 | 55 (14.8)                | 0.56    | 20 (20.0) | 77 (11.4)  | 0.015  |
| Sleep apnea                            | 11 (11.1)                 | 21 (5.7)                 | 0.05    | 13 (13.0) | 55 (8.2)   | 0.11   |
| PAD treatment history                  | Amputation* 1 (1.0)        | 2 (0.5)                  | 0.51    | 3 (3.0)  | 10 (1.5)   | 0.23   |
|                                        | PAD bypass 10 (10.1)       | 17 (4.6)                 | 0.036   | 12 (12.0) | 60 (8.9)   | 0.32   |
|                                        | PAD endarterectomy* 2 (2.0) | 11 (3.0)                | 1.00    | 3 (3.0)  | 21 (3.1)   | 1.00   |
|                                        | PAD angioplasty 24 (24.2)  | 70 (18.9)                | 0.23    | 19 (19.0) | 134 (19.9) | 0.83   |
|                                        | Cilostazol 5 (5.1)         | 23 (6.2)                 | 0.66    | 6 (6.1)  | 42 (6.3)   | 0.94   |
|                                        | Antiplatelet therapy 75 (75.8) | 248 (67.2)            | 0.10    | 70 (70.7) | 448 (66.9) | 0.45   |
|                                        | Statin 67 (67.7)           | 253 (68.6)               | 0.87    | 65 (65.7) | 481 (71.8) | 0.21   |
| PAD characteristics on presentation    | Symptoms                  |                            |         |         |
|                                        | New onset 53 (53.5)        | 191 (51.5)               |         | 50 (50.0) | 360 (53.5) |         |
|                                        | Exacerbation 46 (46.5)     | 180 (48.5)               | 0.72    | 50 (50.0) | 313 (46.5) | 0.51   |

(Continued)
breakdown of the types of depression treatment by sex and depressive symptom status for this cohort is provided in Table 2. In both men and women, patients with depressive symptoms were more likely to be younger, avoid care because of cost, and be sedentary compared with their respective counterparts without depressive symptoms; both men and women with depressive symptoms were less likely to be married compared with those without such symptoms (Table 2).

| Characteristics               | Women PHQ-8 ≥10 | Women PHQ-8 <10 | Men PHQ-8 ≥10 | Men PHQ-8 <10 | P Value | P Value |
|-------------------------------|----------------|----------------|--------------|--------------|---------|---------|
| ABI                           | 0.68±0.20      | 0.64±0.18      | 0.68±0.20    | 0.67±0.19    | 0.06    | 0.88    |
| Rutherford category           | 0.57           |                |              |              |         |         |
| Mild claudication             | 20 (20.8)      | 75 (20.7)      | 18 (18.0)    | 169 (25.5)   |         |         |
| Moderate claudication         | 46 (47.9)      | 193 (53.2)     | 39 (39.0)    | 323 (48.6)   |         |         |
| Severe claudication           | 30 (31.3)      | 95 (26.2)      | 43 (43.0)    | 172 (25.9)   |         |         |
| Duration of pain, mo*         |                |                |              |              |         |         |
| <1                            | 3 (3.7)        | 7 (2.1)        | 1 (1.2)      | 19 (3.3)     |         |         |
| 1–6                           | 21 (25.9)      | 108 (33.1)     | 15 (17.9)    | 176 (30.4)   |         |         |
| 7–12                          | 18 (22.2)      | 60 (18.4)      | 21 (25.0)    | 89 (15.4)    | 0.47    | 0.023   |
| >12                           | 39 (48.1)      | 151 (46.3)     | 47 (56.0)    | 294 (50.9)   |         |         |
| Symptoms                      |                |                |              |              |         |         |
| Typical                       | 69 (77.5)      | 291 (84.1)     | 83 (84.7)    | 543 (88.1)   |         |         |
| Atypical                      | 20 (22.5)      | 55 (15.9)      | 15 (15.3)    | 73 (11.9)    | 0.14    | 0.33    |
| Bilateral disease             | 48 (48.5)      | 216 (68.2)     | 55 (55.0)    | 309 (45.9)   | 0.08    | 0.09    |
| Lesion site                   |                |                |              |              |         |         |
| Proximal                      | 29 (29.6)      | 101 (27.4)     | 32 (32.3)    | 185 (27.7)   |         |         |
| Distal                        | 19 (19.4)      | 130 (35.2)     | 25 (25.3)    | 198 (29.6)   |         |         |
| Both                          | 50 (51.0)      | 138 (37.4)     | 42 (42.4)    | 285 (42.7)   | 0.007   | 0.54    |
| PAD treatment after enrollment|                |                |              |              |         |         |
| Cilostazol                    | 6 (6.1)        | 56 (15.2)      | 8 (8.1)      | 77 (11.5)    | 0.017   | 0.31    |
| Antiplatelet therapy          | 80 (80.8)      | 288 (78.0)     | 79 (79.8)    | 504 (75.2)   | 0.55    | 0.32    |
| Statin                        | 74 (74.7)      | 296 (80.2)     | 75 (75.8)    | 554 (82.7)   | 0.23    | 0.10    |
| Smoking cessation advice (among smokers) | 47 (88.7) | 106 (65.4) | 0.001 | 40 (80.0) | 191 (62.4) | 0.15 |
| Unsupervised PAD exercise therapy | 31 (31.3) | 169 (45.6) | 0.010 | 31 (31.0) | 218 (32.4) | 0.78 |
| Supervised PAD exercise therapy | 20 (20.2) | 75 (20.2) | 1.00 | 19 (19.0) | 158 (23.5) | 0.32 |
| Invasive treatment            | 16 (19.8)      | 66 (19.9)      | 22 (25.3)    | 119 (19.3)   | 0.97    | 0.20    |
| Surgical treatment            | 0 (0.0)        | 6 (1.8)        | 5 (5.7)      | 18 (2.8)     | 0.80    | 0.19    |
| Endovascular treatment        | 16 (19.8)      | 62 (18.7)      | 18 (20.7)    | 104 (16.9)   | 0.83    | 0.38    |

Depression severity and treatment at baseline

| PHQ-8 depression score, mean±SD | <0.001 | 14.1±3.7 | 2.7±2.7 | <0.001 |
| Base line antidepressant treatment |     |         |         |        |
| None                            | 54 (54.5) | 277 (74.7) | 0.001 | 66 (66.0) | 594 (88.3) | <0.001 |
| Pharmacologic                   | 24 (24.2) | 55 (88.5) | 17 (17.0) | 54 (8.0) |     |         |
| Counseling                      | 4 (4.0) | 9 (9.6) | 3 (3.0) | 9 (1.3) | | |
| Both                            | 17 (17.2) | 30 (31.9) | 14 (14.0) | 16 (2.4) | | |

Values are listed as number (percentage), unless otherwise described. ABI indicates ankle-brachial index; CAD, coronary artery disease; PAD, peripheral artery disease; and PHQ-8, 8-Item Patient Health Questionnaire.

Includes all covariates used in modeling by PHQ-8 ≥10. Covariates include age, country, White race, avoiding care because of cost, high school education, exacerbation of symptoms, bilateral disease, smoking, history of diabetes mellitus, coronary artery disease, sleep apnea, and ABI. Continuous variables were compared using the Student t test. Categorical variables were compared using the χ² or the Fisher exact test (race, health insurance, smoking status, amputation, PAD endarterectomy, and duration of pain).
Table 3. Unadjusted Mean PAQ and EQ-5D VAS Scores in Patients With and Without Depressive Symptoms at Baseline and 3, 6, and 12 Months, Stratified by Sex

| Variable | PHQ-8 Score ≥10 (Baseline) |  |  |  |  |  |  |  |
|----------|-----------------------------|------|---|---|---|---|---|
|          | Women | Men | | | | | |
|          | Yes (n=99) | No (n=371) | PaQ summary score, mean±SD | Yes (n=100) | No (n=673) | PaQ summary score, mean±SD | P Value* |
| Baseline | 24.7±16.8 | 48.9±19.7 | 24.2 | 29.2±19.5 | 56.1±19.3 | 26.9 | 0.09 |
| 3 mo     | 45.9±27.5 | 66.6±23.9 | 20.7 | 51.2±28.6 | 71.7±21.7 | 20.5 | 0.22 |
| 6 mo     | 52.7±26.8 | 70.5±24.4 | 17.8 | 53.1±25.7 | 73.7±22.1 | 20.6 | 0.93 |
| 12 mo    | 47.0±28.2 | 68.7±24.8 | 21.7 | 56.6±28.0 | 75.5±22.7 | 18.9 | 0.038 |
| EQ-5D VAS, mean±SD | | | | | | | |
| Baseline | 55.7±21.9 | 68.0±18.7 | 12.3 | 49.7±19.8 | 69.2±17.3 | 19.5 | 0.047 |
| 3 mo     | 58.5±19.9 | 70.8±18.9 | 12.3 | 53.8±23.1 | 72.8±15.6 | 19 | 0.16 |
| 6 mo     | 60.4±21.3 | 73.2±17.2 | 12.8 | 57.2±22.2 | 71.5±16.4 | 14.3 | 0.37 |
| 12 mo    | 58.5±19.5 | 71.6±17.9 | 13.1 | 58.1±18.9 | 72.5±16.1 | 14.4 | 0.89 |

Continuous variables were compared using Student t test. PAQ indicates Peripheral Artery Questionnaire; PHQ-8, 8-Item Patient Health Questionnaire; and VAS, Visual Analogue Scale.

*P values for differences in PAQ summary and EQ-5D VAS scores between women and men with depressive symptoms (PHQ-8 ≥10).
depressive symptoms had lower scores compared with all other groups, but no differences were noted for men whose depressive symptoms were moderate-severe at 3 and 12 months or for men with mild symptoms at 6 months (Table S4).

For the sensitivity analysis as it relates to our GLM modeling, we examined the association between sex and health status outcomes over time, without including depressive symptoms in the fully adjusted GLM. In that model, women scored an average of 6.4 points lower than men (women versus men, −6.4; 95% CI, −8.5 to −4.3; \(P<0.0001\)). After adding depressive symptoms to the adjusted model, this difference decreased to 5.2 points in the adjusted model (women versus men, −5.2; 95% CI, −7.2 to −3.3; \(P<0.0001\)). Depressive symptoms explained 19% ([6.4–5.2]/6.4) of the difference in outcomes between the 2 sexes.

To assess for nonresponse bias, we performed a second sensitivity analysis, comparing those with complete follow-up with those without complete follow-up. Large differences (standardized difference >10%) between the 2 groups, which were not already adjusted for in the main analyses, were duration of pain, lesion site, Rutherford category, history of chronic kidney disease, and history of amputation (Table S5). Addition of these covariates to the main analyses yielded similar results for both PAQ summary scores and EQ-5D VAS at baseline and 3, 6, and 12 months (Figure and Figure S1).

DISCUSSION

Our study demonstrates that a disproportionately higher percentage of women are affected by depressive symptoms when they seek specialty care for new or worsening PAD symptoms, with rates almost twice that observed in men. Experiencing clinically significant depressive symptoms is associated with enormous gaps in their 1-year health status recovery patterns compared with health status levels that are typically seen in their nondepressed counterparts, up to twice the magnitude that is defined as a minimally clinically important difference (Poghni, Peri-Okonny, MD, unpublished data, 2019), leaving patients with depressive symptoms at a disadvantaged position to optimally benefit from the PAD treatments that are offered to them. Although the effect size for the association between depressive symptoms and health status changes over time did not differ by sex, women are disproportionately affected given the increased prevalence of depressive symptoms observed in women. Depressive symptoms also explained about a fifth of the variation seen in health status differences by sex documented in the year following a PAD diagnosis.

Our study provides a unique perspective; it prospectively followed up patients who were dealing with new or recurrent symptoms of PAD and were actively seeking specialty care. This similar time point of identification in the clinical pathway for PAD allowed us to prospectively reconstruct the 1-year health status trajectory in men and women by patients’ depressive symptoms at the time of seeking PAD care. Also notable is that our patients were included before they were assigned to treatment, and regardless of whether they underwent invasive versus noninvasive management of their disease, which is different from most other available PAD databases.38,39
Despite the enormous patient and economic burden associated with both depression\textsuperscript{39} and PAD,\textsuperscript{10,41} we are just starting to understand the potential impact of how mental health concerns may complicate PAD treatment and outcomes. Although it has been demonstrated in coronary artery disease that depressive symptoms are disproportionately present in women compared with men, and that these symptoms are linked with adverse clinical and health status outcomes,\textsuperscript{19,42–44} the association between depressive symptoms and PAD-specific health status outcomes and how this may differ by sex have not been studied in PAD.

Various reasons for an increased depressive symptom burden in women with cardiovascular disease have been studied. Of the factors studied, socioeconomic factors may partially explain as to why women may experience this increased vulnerability.\textsuperscript{45,46} In support of this, we found that less than half of the overall female cohort as well as only one third of those with clinically relevant depressive symptoms were married, and more women than men avoided care because of cost. It is unknown whether any biological sex differences specific to PAD explain some of the differences observed. We did demonstrate in our study that women had lower ABIs, indicating more advanced disease as well as bilateral disease. We did not find any evidence for differential PAD treatment patterns or quality of PAD care by sex. A bias toward undertreatment of depressive symptoms in the context of PAD specialty care was present as only a third of patients were receiving care and/or follow-up for their depressive symptoms, with the lowest treatment rates for men.

Having a depressed mood has potentially major implications for the success of patients’ PAD rehabilitation process and their PAD functioning over time. Depressive symptoms marked a suboptimal PAD recovery pathway, with differences as large as 16 to 21 points on the PAQ summary scale 1 year following active PAD treatment, differences that are almost twice the minimally clinically important difference, as defined from the patients’ perspective. To put these findings further in perspective: in the CLEVER (Supervised Exercise, Stent Revascularization, or Medical Therapy for Claudication Due to Aortoiliac Peripheral Artery Disease: A Randomized Clinical Trial),\textsuperscript{47} differences at 18 months between patients treated with optimal medical therapy only versus those who underwent peripheral stenting were 24 points on the PAQ summary scale; and for optimal medical therapy versus supervised exercise therapy, 13 points. Such large discrepancies in PAD health status outcomes related to patients’ depressive mood demand for more proactive PAD care that can detect and support patients in need, so as to allow them to be successful in managing their PAD.

Although the magnitude of the effect on health status changes over time for depressive symptoms in men and women was not different, women had a higher prevalence of symptoms and higher mean depressive symptom scores at all time periods. Sex differences in PAD-specific health status were also partially explained by depressive symptoms (19%). Whether this has implications for patients’ long-term PAD outcomes needs to be further established, including intervention studies that would include and test depression interventions as a way to maximize PAD rehabilitation outcomes. Preliminary studies have shown that depression is associated with an adverse PAD prognosis as well as with an increased risk of experiencing adverse cardiovascular events.\textsuperscript{29,48,49} In a recent study, depression was independently associated with an elevated risk of amputation, with an even higher risk in those who were not treated with antidepressants.\textsuperscript{50} Whether the higher rates of depressive symptoms contribute to more advanced disease, lower physical functioning,\textsuperscript{52} and poorer outcomes after lower-extremity revascularization\textsuperscript{17,18} and higher in-hospital mortality\textsuperscript{51} in women remains to be seen. Multidirectional relationships between depressive symptoms and cardiovascular outcomes have been described before in cardiovascular disease, but to a much lesser extent in PAD.\textsuperscript{53} Previous studies were cross-sectional, were small sampled, or did not focus on sex differences. In coronary artery disease, sex differences in quality of care, biological differences, and differences in disease manifestations, as well as interrelatedness with women’s psychosocial profiles, and subsequent clinical outcomes have been well described,\textsuperscript{54} but these associations have yet to be fully studied and understood in PAD.

Future work needs to explore whether these same mechanisms explain women’s increased vulnerability to depressive symptoms in PAD. It is also important to increase the knowledge and awareness of vascular specialists who treat patients with PAD, such that they know that women have a higher prevalence of depressive symptoms from an epidemiological standpoint such that they could be referred for further depression evaluation and treatment as part of an integrated care vision that maximized patients’ outcomes.

Our study must be interpreted in the light of several potential limitations. Our study cohort included patients seen at vascular specialty clinics, and our findings may not be representative of the general PAD population who may not have access to specialty clinics. For this study, we focused on depressive symptoms, and we acknowledge that there are a myriad of mental health concerns, as well as other unmeasured psychosocial and clinical factors, that may be intertwined with depressive symptoms, or that may have also impacted patients’ health status.
In summary, our findings indicate that the burden of depressive symptoms in PAD is substantial, and patients affected by them, especially women, have distinctly worse PAD-specific health status after receiving PAD specialty care. Effect sizes were large and carried over at each follow-up point in the year after seeking PAD treatment. There is a need to explore mechanisms of this increased vulnerability in women. These have been extensively described in other atherosclerotic diseases (e.g., exposure to psychosocial stressors and socioeconomic factors), like acute myocardial infarction. The problem is not limited to women alone; among men, too, patients who are dealing with depressive symptoms have worse PAD health outcomes over time. Depressive symptoms in older, chronic disease populations, such as PAD, should be a continuous focus of its multidisciplinary treatment so as to ensure quality PAD care and optimize outcomes. In conclusion, depression warrants screening and treatment in its own right, but especially so in PAD, it is imperative to pay attention to this problem.

ARTICLE INFORMATION

Received October 2, 2019; accepted June 22, 2020.

Affiliations

From the Vascular Medicine Outcomes Program, Section of Cardiovascular Medicine, Department of Internal Medicine (G.J.), C.M.-H., K.G.S.), and Department of Internal Medicine (M.B., R.S.), Yale University School of Medicine, New Haven, CT; Saint Luke’s Mid America Heart Institute, Kansas City, MO (K.G., P.G.J., J.A.S.); University of Missouri–Kansas City, MO (P.G.J., J.A.S.); and Department of Emergency Medicine, Yale School of Medicine, New Haven, CT (B.S.).

Acknowledgments

We thank all patients who participated in this study, allowing us to conduct multifaceted research in peripheral artery disease.

Sources of Funding

Research reported in this article was partially funded through the Patient-Centered Outcomes Research Institute (PCORI) Award (IP2 PI000573-01; CE-1304-6677) and an unrestricted grant by Gore. The statements in this article are solely the responsibility of the authors and do not necessarily represent the views of the PCORI, its Board of Governors, or its Methodology Committee. All articles for the PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Artery Disease Investigating Trajectories) registry are prepared by independent authors who are not governed by the funding sponsors and are reviewed by an academic publications committee before submission. The funding organizations and sponsors of the study had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclosures

Dr Mena-Hurtado is a consultant for Bard, Cook, Medtronic, Abbott, Boston Scientific, Optum Labs LLC and Cardinal Health. Dr Sperturn is supported by grants from Gilead, Genentech, Lilly, Amoryce, and EvalHeart; and has a patent Seattle Angina Questionnaire with royalties paid. Dr Smolideren is supported by an unrestricted research grant from Terumo and is a consultant for Optum Labs LLC. The remaining authors have no disclosures to report.

Supplementary Materials

Tables S1–S5

Figure S1

REFERENCES

1. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329–1340.

2. Sampson UK, Fowkes FG, McDermott MM, Criqui MH, Aboyans V, Norman PE, Forouzanfar MH, Naghavi M, Song Y, Harrell FE Jr, et al. Global and regional burden of death and disability from peripheral artery disease: 21 world regions, 1990 to 2010. Glob Heart. 2014;9:145–158.e621.

3. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenland K, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:480–486.

4. Sarnak MJ, Levey AS, Schoolwerth AG, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiskie BL, Kelepouris E, Klag MJ, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42:1050–1065.

5. Joosten MM, Pai JK, Bertoia ML, Rimm EB, Spiegelman D, Mittleman MA, Mukamal KJ. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA. 2012;308:1660–1667.

6. Hirsch AT, Criqui MH, Treut-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krock SH, Hunninghake DB, Comerota AJ, Walsh ME, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–1324.

7. Grenon SM, Vittinghoff E, Owens CD, Conte MS, Whooley M, Cohen BE. Peripheral artery disease and risk of cardiovascular events in patients with coronary artery disease: insights from the Heart and Soul Study. Vasc Med. 2013;18:176–184.

8. Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality implications. Circulation. 2006;114:688–699.

9. Steg PG, Bhatt DL, Wilson PW, D’Agostino R Sr, Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JI, Ikeda Y, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197–1206.

10. Mahoney EM, Wang K, Cohen DJ, Hirsch AT, Alberts MJ, Eagle K, Mosse F, Jackson JD, Steg PG, Bhatt DL, et al. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2008;1:38–45.

11. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey. 1999–2000. Circulation. 2004;110:738–743.

12. Kullo IJ, Bailey KR, Kardia SL, Mosley TH Jr, Boerwinkle E, Turner ST. Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study. Vasc Med. 2003;8:237–242.

13. Zheng ZJ, Rosamond WD, Chambless LE, Nieto FJ, Barnes RW, Hutchinson RG, Tyrode HA, Heiss G; ARIC Investigators. Lower extremity arterial disease assessed by ankle-brachial index in a middle-aged population of African Americans and whites: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Prev Med. 2005;29:42–49.

14. Gofin R, Kark JD, Friedlander Y, Lewis BS, Witt H, Stein Y, Gotsman MS. Peripheral vascular disease in a middle-aged population sample: the Jerusalem Lipid Research Clinic Prevalence Study. Isr J Med Sci. 1997;23:157–167.

15. McDermott MM, Greenland P, Liu K, Criqui MH, Guralnik JM, Cellic C, Chan C. Sex differences in peripheral arterial disease: leg symptoms and physical functioning. J Am Geriatr Soc. 2003;51:222–228.

16. Collins TC, Suarez-Almazor M, Bush RL, Petersen NJ. Gender and peripheral arterial disease. J Am Board Fam Med. 2006;19:132–140.

17. Nguyen LL, Brahmanandam S, Bandoky DF, Belkin M, Cloves AW, Moneta GL, Conte MS. Female gender and oral anticoagulants are associated with wound complications in lower extremity vein bypass: an analysis of 1404 operations for critical limb ischemia. J Vasc Surg. 2007;46:1191–1197.

Jelani et al Sex, Depressive Symptoms, and Health Status in PAD

Sex, Depressive Symptoms, and Health Status in PAD

J Am Heart Assoc. 2020;9:e014583. DOI: 10.1161/JAHA.119.014583
opportunities to understand quality and outcomes of peripheral vascular interventions: the ACC NCDR PVI Registry. Am Heart J. 2019;216:74–81.

39. Cronenwett JL, Kraiss LW, Cambria RP. The Society for Vascular Surgery Vascular Quality Initiative. J Vasc Surg. 2012;55:1529–1537.

40. Roehrig C. Mental disorders top the list of the most costly conditions in the United States: $201 billion. Health Aff (Millwood). 2016;35:1130–1135.

41. Mahoney EM, Wang K, Keo HH, Duval S, Smolderen KG, Cohen DJ, Steg G, Bhatt DL, Hirsch AT. Reduction of Atherothrombosis for Continued Health Enjoyment Investigators. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circ Cardiovasc Qual Outcomes. 2010;3:642–651.

42. Smolderen KG, Spertus JA, Gosch K, Dreyer RP, D’Onofrio G, Lichtman JH, Geda M, Beltrame J, Safdar B, Bueno H, et al. Depression treatment and health status outcomes in young patients with acute myocardial infarction: insights from the VIRGO Study (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients). Circulation. 2017;135:1762–1764.

43. Smolderen KG, Buchanan DM, Gosch K, Whooley M, Chan PS, Vaccarino V, Parashar S, Shah AJ, Ho PM, Spertus JA. Depression treatment and 1-year mortality after acute myocardial infarction: insights from the TRIUMPH Registry (Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients’ Health Status). Circulation. 2017;135:1681–1689.

44. Rutledge T, Vaccarino V, Johnson BD, Bittner V, Olson MB, Linke SE, Cornell CE, Eteiba W, Sheps DS, Francis J, et al. Depression and cardiovascular health care costs among women with suspected myocardial ischemia: prospective results from the WISE (Women’s Ischemia Syndrome Evaluation) Study. J Am Coll Cardiol. 2009;53:176–183.

45. Jo SJ, Yim HW,Bang MH, Lee MO, Jun TY, Choi JS, Lee MS, Lee WC, Park YM. The association between economic status and depressive symptoms: an individual and community level approach. Psychiatry Investig. 2011;8:194–200.

46. Aseltine RH Jr, Kessler RC. Marital disruption and depression in a community sample. J Health Soc Behav. 1993;34:237–251.

47. Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER III, Reynolds MR, Massaro JM, Lewis BA, Cerezo J, Oldenburg NC, et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER (Women’s Ischemia Syndrome Evaluation) Study. J Am Coll Cardiol. 2017;69:205–214.

48. Smolderen KG, Bosl D, Bittner V, Olson MB, Steg G, Bhatt DL, Hirsch AT; Reduction of Atherothrombosis for Continued Health Enjoyment Investigators. Impact of mental disorders on the outcome of arterial procedures in the lower extremity. Health Aff (Millwood). 2012;31:33–40.

49. Smolderen KG, Plomondon ME, Armstrong EJ, Hess E, Waldo S, Tsai J, Zieske S, Southerland MA, Newby KE, et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER (Women’s Ischemia Syndrome Evaluation) Study. J Am Coll Cardiol. 2017;69:205–214.

50. Smolderen KG, Buchanan DM, Gosch K, Whooley M, Chan PS, Vaccarino V, Parashar S, Shah AJ, Ho PM, Spertus JA. Depression treatment and 1-year mortality after acute myocardial infarction: insights from the VIRGO Study (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients). Circulation. 2017;135:1762–1764.

51. Smolderen KG, Buchanan DM, Gosch K, Whooley M, Chan PS, Vaccarino V, Parashar S, Shah AJ, Ho PM, Spertus JA. Depression treatment and 1-year mortality after acute myocardial infarction: insights from the VIRGO Study (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients). Circulation. 2017;135:1762–1764.

52. Smolderen KG, Spertus JA, Gosch K, Dreyer RP, D’Onofrio G, Lichtman JH, Geda M, Beltrame J, Safdar B, Bueno H, et al. Depression treatment and health status outcomes in young patients with acute myocardial infarction: insights from the VIRGO Study (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients). Circulation. 2017;135:1762–1764.
Supplemental Material
**Table S1. Health Status Outcomes (PAQ summary scores and EQ-5D VAS) by Severity of Depressive Symptoms at Baseline, 3, 6 and 12 months for the Entire Cohort.**

|                      | PHQ-8 Depressive Symptoms Severity (Mean±SD) |
|----------------------|---------------------------------------------|
|                      | None (n=767)                                 | Mild (n=277)                                 | Moderate-Severe (n=199) |
| *PAQ Summary (Baseline)* | 57.4 ± 18.8                                 | 42.9 ± 18.3                                 | 26.9 ± 18.3             |
| PAQ Summary (3 Months) | 72.5 ± 21.6                                 | 62.5 ± 23.6                                 | 48.7 ± 28.1             |
| PAQ Summary (6 Months) | 75.1 ± 21.7                                 | 65.4 ± 24.9                                 | 52.9 ± 26.1             |
| PAQ Summary (12 Months) | 75.8 ± 22.2                                | 65.4 ± 26.0                                 | 51.9 ± 28.4             |
| EQ5D VAS (Baseline)   | 71.2 ± 17.1                                 | 62.1 ± 18.0                                 | 52.8 ± 21.0             |
| EQ5D VAS (3 Months)   | 74.4 ± 16.0                                 | 65.4 ± 17.5                                 | 56.1 ± 21.7             |
| EQ5D VAS (6 Months)   | 74.1 ± 15.7                                 | 66.2 ± 17.9                                 | 58.8 ± 21.8             |
| EQ5D VAS (12 Months)  | 74.7 ± 15.4                                 | 65.0 ± 18.3                                 | 58.3 ± 19.1             |

Depressive Symptom Severity was defined as; No Depressive Symptoms (PHQ-8 score < 5); Mild Depressive Symptoms (PHQ-8 score ≥ 5 and ≤ 9); Moderate-Severe (PHQ-8 score ≥ 10).

PAQ, Peripheral Artery Questionnaire; PHQ-8, 8-item Patient Health Questionnaire; VAS, Visual Analogue Scale.

* P-values for the overall comparisons and for pairwise comparisons between “None” and “Mild” depressive symptoms were derived (all p-values <0.001)
Table S2. Health Status Outcomes (PAQ summary scores and EQ-5D) by severity of depressive symptoms at baseline, 3, 6 and 12 months for women.

| PHQ-8 Depressive Symptoms Severity (Mean±SD) | None | Mild | Moderate-Severe |
|---------------------------------------------|------|------|-----------------|
| PHQ-8 Depressive Symptoms Severity (Mean±SD) |      |      |                 |
| PAQ: Summary (Baseline)                     | 53.0 ± 19.4 | 39.5 ± 17.1 | 24.7 ± 16.8 |
| PAQ: Summary (3 Months)                     | 69.9 ± 23.0 | 58.8 ± 24.3 | 45.9 ± 27.5 |
| PAQ: Summary (6 Months)                     | 73.7 ± 22.7 | 62.7 ± 26.8 | 52.7 ± 26.8 |
| PAQ: Summary (12 Months)                    | 71.5 ± 23.8 | 62.1 ± 26.0 | 47.0 ± 28.2 |
| EQ5D VAS (Baseline)                         | 70.8 ± 18.1 | 61.8 ± 18.7 | 55.7 ± 21.9 |
| EQ5D VAS (3 Months)                         | 73.1 ± 18.4 | 65.4 ± 19.1 | 58.5 ± 19.9 |
| EQ5D VAS (6 Months)                         | 74.8 ± 16.2 | 69.1 ± 18.7 | 60.4 ± 21.3 |
| EQ5D VAS (12 Months)                        | 74.9 ± 16.1 | 63.9 ± 19.5 | 58.5 ± 19.5 |
Depressive Symptom Severity was defined as; No Depressive Symptoms (PHQ-8 score < 5); Mild Depressive Symptoms (PHQ-8 score ≥ 5 and ≤ 9); Moderate-Severe (PHQ-8 score ≥ 10)

*P-values for the overall comparisons and for pairwise comparisons between “None” and “Mild” depressive symptoms were derived (all p-values <0.001).

Continuous variables compared using Linear Trend test.
Categorical variables compared using Mantel-Haenszel Trend test.

PAQ, Peripheral Artery Questionnaire; PHQ-8, 8-Item Patient Health Questionnaire; VAS, Visual Analogue Scale.
Table S3. Health Status Outcomes (PAQ summary scores and EQ-5D VAS) by severity of depressive symptoms at baseline, 3, 6 and 12 months for men.

| PHQ-8 Depressive Symptoms Severity (Mean±SD) | None n=510 | Mild n=163 | Moderate-Severe n=100 |
|---------------------------------------------|------------|------------|-----------------------|
| *PAQ Summary (Baseline)                     | 59.6 ± 18.1| 45.4 ± 18.9| 29.2 ± 19.5           |
| PAQ Summary (3 Months)                       | 73.8 ± 20.9| 65.0 ± 22.9| 51.2 ± 28.6           |
| PAQ Summary (6 Months)                       | 75.8 ± 21.3| 67.1 ± 23.6| 53.1 ± 25.7           |
| PAQ Summary (12 Months)                      | 77.9 ± 21.0| 67.7 ± 25.9| 56.6 ± 28.0           |
| EQ5D VAS (Baseline)                           | 71.5 ± 16.6| 62.4 ± 17.5| 49.7 ± 19.8           |
| EQ5D VAS (3 Months)                           | 75.1 ± 14.6| 65.3 ± 16.5| 53.8 ± 23.1           |
| EQ5D VAS (6 Months)                           | 73.8 ± 15.5| 64.3 ± 17.1| 57.2 ± 22.2           |
| EQ5D VAS (12 Months )                         | 74.6 ± 15.0| 65.8 ± 17.6| 58.1 ± 18.9           |

Depressive Symptom Severity was defined as; No Depressive Symptoms (PHQ-8 score <5); Mild Depressive Symptoms (PHQ-8 score ≥ 5 and ≤ 9); Moderate-Severe (PHQ-8 score ≥ 10).

Continuous variables compared using Linear Trend test.

Categorical variables compared using Mantel-Haenszel Trend test.
PHQ-8, 8-Item, Patient Health Questionnaire; SD, Standard Deviation; PAQ, Peripheral Artery Questionnaire; VAS, Visual Analogue Scale.

*P-values for the overall comparisons and for pairwise comparisons between “None” and “Mild” depressive symptoms were derived (all p-values <0.001).
Table S4. Post Hoc Testing for Comparisons of Differences in Mean Health Status Scores (PAQ summary scores and EQ-5D VAS) and Standard Deviations By Sex and Severity of Depressive Symptoms at baseline, 3, 6 and 12 months.

|                  | PAQ Summary Mean Differences (SE) | P-value | EQ-5D VAS Mean Differences ± SD | P-value |
|------------------|-----------------------------------|---------|--------------------------------|---------|
| **Baseline**     |                                   |         |                                |         |
| Men (severe)     | 4.45 (2.61)                       | 0.088   | -6.05 (2.61)                   | 0.020   |
| Men (mild)       | 20.67 (2.35)                      | <0.0001 | 6.64 (2.33)                    | 0.0045  |
| Men (none)       | 34.87 (2.02)                      | <0.0001 | 15.70 (2.01)                   | <0.0001 |
| Women (mild)     | 14.77 (2.53)                      | <0.0001 | 6.09 (2.51)                    | 0.015   |
| Women (none)     | 28.32 (2.18)                      | <0.0001 | 15.07 (2.16)                   | <0.0001 |
| **3 Months**     |                                   |         |                                |         |
| Men (severe)     | 5.30 (3.51)                       | 0.13    | -4.69 (2.64)                   | 0.07    |
| Men (mild)       | 19.03 (3.16)                      | <0.0001 | 6.81 (2.39)                    | 0.004   |
| Men (none)       | 27.88 (2.75)                      | <0.0001 | 16.60 (2.07)                   | <0.0001 |
| Women (mild)     | 12.82 (3.44)                      | 0.0002  | 6.84 (2.60)                    | 0.0087  |
| Women (none)     | 23.93 (2.95)                      | <0.0001 | 14.55 (2.22)                   | <0.0001 |
| **6 Months**     |                                   |         |                                |         |
| Men (severe)     | 0.37 (3.69)                       | 0.92    | -3.15 (2.77)                   | 0.26    |
| Men (mild)       | 14.38 (3.27)                      | <0.0001 | -3.89 (2.45)                   | 0.11    |
|                          | PAQ Summary Mean Differences (SE) | P-value | EQ-5D VAS Mean Differences ± SD | P-value |
|--------------------------|-----------------------------------|---------|---------------------------------|---------|
| Men (none)               | 23.14 (2.86)                      | <0.0001 | 13.39 (2.14)                    | <0.0001 |
| Women (mild)             | 10.06 (3.58)                      | 0.005   | 8.73 (2.69)                     | 0.0012  |
| Women (none)             | 21.04 (3.06)                      | <0.0001 | 14.46 (2.29)                    | <0.0001 |

**12 Months**

|                          | PAQ Summary Mean Differences (SE) | P-value | EQ-5D VAS Mean Differences ± SD | P-value |
|--------------------------|-----------------------------------|---------|---------------------------------|---------|
| Men (severe)             | 9.59 (3.89)                       | 0.013   | -0.41 (2.74)                    | 0.88    |
| Men (mild)               | 20.66 (3.44)                      | <0.0001 | 7.35 (2.42)                     | 0.0024  |
| Men (none)               | 30.91 (3.01)                      | <0.0001 | 16.12 (2.11)                    | <0.0001 |
| Women (mild)             | 15.12 (3.72)                      | <0.0001 | 5.39 (2.61)                     | 0.039   |
| Women (none)             | 24.44 (3.22)                      | <0.0001 | 16.44 (2.26)                    | <0.0001 |

Depressive Symptom Severity was defined as; No Depressive Symptoms (PHQ-8 score < 5); Mild Depressive Symptoms (PHQ-8 score ≥ 5 and ≤ 9); Moderate-Severe (PHQ-8 score ≥ 10). The reference category was women with severe depressive symptoms for all comparisons.

PHQ-8, 8-Item Patient Health Questionnaire; PAQ, Peripheral Artery Questionnaire; VAS, Visual Analogue Scale; SD, Standard Error.
### Table S5. Baseline Characteristics for Those With Complete and Incomplete Follow-Up.

|                      | Follow-up          | Total        | p-value | Std. Diff % |
|----------------------|--------------------|--------------|---------|-------------|
|                      | Complete n=980     | Incomplete n=263 |         |             |
| Age, years Mean±SD   | 67.8± 9.2          | 66.8 ±10.3   | 67.6 ±9.4 | 0.107       | 10.8        |
| Race: White          | 821 (83.8)         | 198 (75.3)   | 1019 (82.0) | 0.001       | 21.2        |
| Country              |                    |              |         |             |
| (1) United States    | 592 (60.4)         | 183 (69.6)   | 775 (62.3) |             |             |
| (2) Netherlands      | 311 (31.7)         | 63 (24.0)    | 374 (30.1) |             |             |
| (3) Australia        | 77 (7.9)           | 17 (6.5)     | 94 (7.6)   | 0.023       | 19.4        |
| Health Insurance     | 974(994)           | 262(99.6)    | 1236(99.4) | 1.000       | 3.3         |
| Education High School or above | 677 (69.5) | 174 (67.2) | 851 (69.0) | 0.471 | 5.0 |
| Married              | 580 (59.5)         | 152 (58.0)   | 732 (59.2) | 0.666      | 3.0         |
| Working for pay      | 236 (24.2)         | 57 (21.8)    | 293 (23.6) | 0.416      | 5.7         |
| Avoid care due to cost | 128 (13.2) | 46 (17.6)   | 174 (14.1) | 0.069      | 12.2        |
| Smoke status         |                    |              |         |             |
| (1) Never            | 104 (10.6)         | 28 (10.7)    | 132 (10.6) |             |             |
| (2) Former           | 526 (53.7)         | 122 (46.6)   | 648 (52.2) |             |             |
| (3) Current          | 349 (35.6)         | 112 (42.7)   | 461 (37.1) | 0.089      | 15.2        |
## Duration of pain

| Duration          | New Onset | Exacerbation | Both Lesions | p-value |
|-------------------|-----------|--------------|--------------|---------|
| (1) < 1 Month     | 21 (2.5)  | 9 (4.0)      | 30 (2.8)     |         |
| (2) 1 - 6 Months  | 249 (29.5)| 71 (31.4)    | 320 (29.9)   |         |
| (3) 7 - 12 Months | 153 (18.1)| 35 (15.5)    | 188 (17.6)   |         |
| (4) >12 Months    | 420 (49.8)| 111 (49.1)   | 531 (49.7)   | 0.501   |

## ABI

|       | Mean±SD |       |
|-------|---------|-------|
| <1    | 0.67 ±0.19 | 66 ±0.19 | 67 ±0.19 | 0.805  | 1.7   |
| 1-6   | 0.66 ±0.19 | 66 ±0.19 | 67 ±0.19 |         |       |
| 7-12  | 0.67 ±0.19 | 66 ±0.19 | 67 ±0.19 |         |       |
| >12   | 0.805    | 1.7    |         |         |       |

## Symptoms

|       | New-onset | Exacerbation | p-value |
|-------|-----------|--------------|---------|
| (1)   | 519 (53.0)| 135 (51.3)   | 654 (52.6)| 0.638  | 3.3   |
| (2)   | 461 (47.0)| 128 (48.7)   | 589 (47.4)|         |       |

## Lesion Site

|       | Proximal | Distal | Both | p-value |
|-------|----------|--------|------|---------|
| (1)   | 270 (27.7)| 77 (29.5)| 347 (28.1)| 0.010  | 21.2  |
| (2)   | 277 (28.5)| 95 (36.4)| 372 (30.1)|         |       |
| (3)   | 426 (43.8)| 89 (34.1)| 515 (41.7)|         |       |

## Function: Symptomatic leg

|       | Right leg | Left leg | Both legs | p-value |
|-------|-----------|----------|-----------|---------|
| (1)   | 242 (24.7)| 62 (23.6)| 304 (24.5)| 0.407  | 9.4   |
| (2)   | 252 (25.7)| 59 (22.4)| 311 (25.0)|         |       |
| (3)   | 486 (49.6)| 142 (54.0)| 628 (50.5)|         |       |

## Function: Rutherford category

|       | Mild claudication | Moderate claudication | Severe claudication | p-value |
|-------|-------------------|-----------------------|---------------------|---------|
| (1)   | 215 (22.2)        | 67 (26.3)             | 282 (23.1)          |         |
| (2)   | 478 (49.4)        | 123 (48.2)            | 601 (49.1)          |         |
| (3)   | 275 (28.4)        | 65 (25.5)             | 340 (27.8)          | 0.346   | 10.1  |
| Condition                        | Mean±SD        | Mean±SD        | Mean±SD        | p-value | r    |
|---------------------------------|----------------|----------------|----------------|---------|------|
| **CAD**                         | 381 (38.9)     | 105 (39.9)     | 486 (39.1)     | 0.757   | 2.1  |
| Amputation                      | 8 (0.8)        | 8 (3.0)        | 16 (1.3)       | 0.009   | 16.2 |
| Dyslipidemia                    | 779 (79.5)     | 208 (79.1)     | 987 (79.4)     | 0.886   | 1.0  |
| Hypertension                    | 788 (80.4)     | 205 (77.9)     | 993 (79.9)     | 0.376   | 6.1  |
| Diabetes                        | 319 (32.6)     | 96 (36.5)      | 415 (33.4)     | 0.227   | 8.3  |
| Chronic kidney disease          | 99 (10.1)      | 39 (14.8)      | 138 (11.1)     | 0.030   | 14.3 |
| Chronic back pain               | 136 (13.9)     | 33 (12.5)      | 169 (13.6)     | 0.576   | 3.9  |
| Sleep apnea                     | 82 (8.4)       | 18 (6.8)       | 100 (8.0)      | 0.419   | 5.7  |
| **PHQ-8 Depression Score**      |                |                |                |         |      |
| Mean±SD                         | 4.3 ±4.6       | 6.2 ±6.0       | 4.7± 5.0       | <0.001  | 34.6 |
| **PAQ Summary Score**           |                |                |                |         |      |
| Mean±SD                         | 50.3 ±21.5     | 45.5 ±22.6     | 49.3 ±21.8     | 0.001   | 21.8 |
| **EQ-5D VAS**                   |                |                |                |         |      |
| Mean±SD                         | 67.2± 18.7     | 62.7±20.9      | 66.2 ±19.3     | 0.001   | 22.6 |

Continuous variables were compared using the Student's T-test.

Categorical variables were compared using the Chi-square or Fisher's exact test (Health insurance and Amputation).

SD, Standard Deviation; Std. Diff, Standardized Difference; ABI, Ankle Brachial Index; CAD, Coronary Artery Disease; PHQ-8, 8-item Patient Health Questionnaire; PAQ, Peripheral Artery Questionnaire; VAS, Visual Analogue Scale.
Figure S1. Sensitivity Plots Showing Differences in PAQ summary scores (A) and EQ-5D VAS (B) after additional adjustment for co-variates with a > 10% standardized difference between those with complete versus incomplete follow-up.
These co-variates included duration of pain, lesion site, Rutherford category, history of chronic kidney disease and history of amputation. Abbreviations: PAQ, Peripheral Artery Questionnaire; VAS: Visual Analogue Scale.